Safety and efficacy of two doses of belzutifan in patients with advanced RCC: Results of the randomized phase II LITESPARK-013 study
Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review
Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation study
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist’s Point of View
Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma
European Urology Oncology, October 2022
Oncological outcomes of delayed nephrectomy after optimal response to immune checkpoint inhibitors for metastatic renal cell carcinoma
89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma – results from phase 3 ZIRCON study
Local treatment of recurrent renal cell carcinoma may have a significant survival effect across all risk-of-recurrence groups
Phase II study of axitinib prior to partial nephrectomy to preserve renal function: An interim analysis of the PADRES clinical trial
Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy. I agree Read More